title: Potential of cranberry powder for management of hyperglycemia using in vitro models.
abstract: Aqueous solutions of two different cranberry powders (CP and CP-SAB) were evaluated for organic acids, sugars, total phenolics, antioxidant activity based on the 2,2-diphenyl-1-picrylhydrazyl radical scavenging assay, and functionality such as in vitro inhibition of α-amylase, α-glucosidase, and angiotensin I-converting enzyme (ACE) relevant for potential management of hyperglycemia and hypertension linked to type 2 diabetes. The total phenolics content was 11 and 51 mg/g of sample dry weight for CP and CP-SAB, respectively. p-Coumaric acid and quercetin derivatives were the main phenolic compounds identified in the cranberry powders. CP-SAB had α-glucosidase inhibitory activity that increased with increased dose (1-5 mg/mL) from 60% to 100% inhibition. There was limited amount of α-amylase inhibitory activity that reached a maximum of 40% inhibition at 5 mg/mL treatment. Significant ACE inhibitory activity was detected for CP-SAB at 100 and 200 mg/mL sample concentrations. These in vitro results indicate the potential of cranberry powders as dietary supplement and food-based strategies for potential hyperglycemia management. This biochemical rationale provides the basis for further design of animal and clinical studies using standardized extracts.
authors.affiliation: Department of Food Science, University of Massachusetts, Amherst, MA 01003, USA.
authors.forename: Marcia da Silva
authors.initials: Mda S
authors.lastname: Pinto
authors.forename: Reza
authors.initials: R
authors.lastname: Ghaedian
authors.forename: Rahul
authors.initials: R
authors.lastname: Shinde
authors.forename: Kalidas
authors.initials: K
authors.lastname: Shetty
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000975:Antioxidants / Q000032:analysis / Q000494:pharmacology; D002241:Carbohydrates / Q000032:analysis; D002264:Carboxylic Acids / Q000032:analysis; D003373:Coumaric Acids / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D019587:Dietary Supplements; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005638:Fruit / Q000737:chemistry*; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D010636:Phenols / Q000032:analysis; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology*; D011208:Powders; D011422:Propionates; D011794:Quercetin / Q000032:analysis; D029799:Vaccinium macrocarpon / Q000737:chemistry*; D000516:alpha-Amylases / Q000037:antagonists & inhibitors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000975:Antioxidants; D002241:Carbohydrates; D002264:Carboxylic Acids; D003373:Coumaric Acids; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D010636:Phenols; D010936:Plant Extracts; D011208:Powders; D011422:Propionates; D011794:Quercetin; D000516:alpha-Amylases; C495469:p-coumaric acid